2016_BT PROSTATE CANCER COURSE BOOK

1999 2016 ; the evolution ! -

• Ideas progressively changed … • Risk groups ; should brachytherapy as monotherapy be reserved to low-risk patients ? • What about age ? • What about the biopsies ?( Percentage of involved samples, microfoci, bilaterality …) • What about median lobes and obstructive syndroms ? • Which role for MRI ?